Skip over global navigation links
U.S. Department of Health and Human Services

BARDA funds advanced development of drug to treat bone marrow injury associated with acute radiation syndrome

Date: September 15, 2011

Company: Neumedicines, Inc., Pasadena, Calif.

Contract amount: Approximately $17 million over 18 months and can be extended for a total of five years and up to $274 million

About the contract: Neumedicines will conduct studies to begin evaluating the safety and efficacy of a drug to treat bone marrow injuries from exposure to high levels of radiation, such as after a nuclear attack, and will develop manufacturing processes for the drug and manufacture small amounts of the drug for testing. The contract builds on work conducted under a BARDA contract issued in 2008. Under that contract, Neumedicines conducted studies indicating that the drug known as NMIL12-1 or HemaMax mitigates bone marrow damage caused by acute ionizing (damaging) radiation 24 hours after a person is exposed to radiation and that the drug promotes regeneration of multiple types of blood cells.

Additional information: BARDA is seeking additional proposals for products that potentially could treat or illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear denotation or radiation accident. 

Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at

Procurement Announcement:  Contract Award under BAA-BARDA-09-34

PHE Newsroom

Submit an Inquiry


Watch, Listen, Subscribe

Facebook Exit Icon Twitter Exit Icon YouTube Exit Icon
Email via GovDelivery Exit Icon LinkedIn Exit Icon

  • This page last reviewed: January 11, 2018